Compare · NVO vs PTPI
NVO vs PTPI
Side-by-side comparison of Novo Nordisk A/S (NVO) and Petros Pharmaceuticals Inc. (PTPI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and PTPI operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO carries a market cap of $174.57B.
- NVO has hit the wire 9 times in the past 4 weeks while PTPI has been quiet.
- NVO has more recent analyst coverage (25 ratings vs 0 for PTPI).
- Company
- Novo Nordisk A/S
- Petros Pharmaceuticals Inc.
- Price
- -
- -
- Market cap
- $174.57B
- -
- 1M return
- +0.27%
- -
- 1Y return
- -19.53%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 9
- 0
- Recent ratings
- 25
- 0
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Petros Pharmaceuticals Inc.
Petros Pharmaceuticals, Inc. engages in identifying, acquiring, developing, and commercializing therapeutics for men's health issues in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company develops H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. It also offers prescription medication, such as Stendra for the treatment of male erectile dysfunction; and vacuum erection devices. Petros Pharmaceuticals, Inc. is based in New York, New York.
Latest NVO
- Novo launches the new Novocare®: Free support program connects people with Wegovy® in addition to home delivery, everyday support, wellness partners and rewards
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo and DJ Khaled team up to take fans behind the scenes of the iconic musician's real-life "Walk, Golf, and Wegovy®" diet and weight-loss routine
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Billions in New Plants, Trillions in Potential Obesity-Drug Revenue Over Two Decades
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
Latest PTPI
- Petros Pharmaceuticals Inc. filed SEC Form 8-K: Bankruptcy or Receivership, Events That Accelerate or Increase a Direct Financial Obligation, Leadership Update
- SEC Form 10-Q filed by Petros Pharmaceuticals Inc.
- New insider Weinstein Robert claimed ownership of 636,004 shares (SEC Form 3)
- Petros Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Director Walker Wayne Remell was granted 375,000 shares, increasing direct ownership by 74% to 881,333 units (SEC Form 4)
- Officer Boctor Fady was granted 375,000 shares, increasing direct ownership by 72% to 894,986 units (SEC Form 4)
- Director Bernstein Bruce was granted 1,875,000 shares, increasing direct ownership by 99% to 3,762,334 units (SEC Form 4)
- Director Silverman Joshua was granted 4,375,000 shares, increasing direct ownership by 99% to 8,790,450 units (SEC Form 4)
- Petros Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update
- SEC Form 10-Q filed by Petros Pharmaceuticals Inc.